Status:
COMPLETED
K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp
Lead Sponsor:
Moberg Pharma AB
Conditions:
Seborrhoeic Eczema of the Scalp
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Seborrhoeic eczema (SE) is a chronic, inflammatory skin disorder confined to areas of the head and trunk where sebaceous glands are most prominent. The severity varies from mild dandruff to exfoliativ...
Eligibility Criteria
Inclusion
- Male or female (including fertile women)
- 18-70 years of age
- Seborrhoeic eczema of the scalp for at least 2 months
- Presenting erythema and desquamation of mild to moderate intensity
- Signed written informed consent
Exclusion
- Seborrhoeic eczema or any other cutaneous disease of the face or scalp requiring a specific topical treatment (corticosteroids, antifungals, selenium sulphide, antibiotics, retinoids, benzoyl peroxide or a-hydroxyacids) during the previous 15 days
- Oral treatment with cyclines, lithium, antifungals or inhaled corticosteroids during the previous month
- Use of systemic corticosteroids and retinoids during the previous 2 months
- Seborrhoeic eczema associated with Parkinson's disease or HIV infection
- Current or any history of ear, nose, and throat carcinoma
- Current or any history of severe concomitant disease according to Investigator's judgement
- Allergy to any of the tested treatment components
- Subject who has been previously enrolled in the phase II study K40-3 investigating Kaprolac® K40
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
201 Patients enrolled
Trial Details
Trial ID
NCT01137331
Start Date
February 1 2008
End Date
April 1 2008
Last Update
June 4 2010
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Läkarhuset Farsta Centrum
Farsta, Sweden
2
Hedgrindhälsan AB
Gävle, Sweden
3
Centrumläkarna
Gothenburg, Sweden
4
Kristinelundskliniken Hudläkarmottagningen
Gothenburg, Sweden